CTAD 2022 and Ctad 2022 View overview page

Lecanemab: a review

Lecanemab: drawbacks to consider

Lecanemab vs aducanumab

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Primary care digital screening tool for Alzheimer’s disease

Remaining challenges in bringing fluid biomarkers into clinical practice

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Bringing the pTau/Aβ42 biomarker into the clinic

Targeting the pancreas to treat Alzheimer’s disease

Promise of microRNAs as Alzheimer’s disease markers

Diabetes-associated cognitive dysfunction

The importance of using systems biology based approaches in AD research

The regulatory role of nicotinic receptors in cognitive functioning

New pivotal study using photobiomodulation in Alzheimer’s treatment

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI

How effective are cholinergic agents beyond MCI?